Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) Trading Down 5.8% – Time to Sell?

by · The Cerbat Gem

Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA – Get Free Report)’s stock price traded down 5.8% on Thursday . The stock traded as low as $21.00 and last traded at $21.03. 218,859 shares were traded during trading, a decline of 18% from the average session volume of 265,954 shares. The stock had previously closed at $22.33.

Analysts Set New Price Targets

Several research firms have weighed in on DMRA. Evercore assumed coverage on shares of Damora Therapeutics, Inc. Common Stock in a research note on Wednesday, March 25th. They issued an “outperform” rating and a $46.00 price objective on the stock. Wedbush started coverage on shares of Damora Therapeutics, Inc. Common Stock in a report on Thursday, May 28th. They set an “outperform” rating and a $35.00 price target for the company. Guggenheim restated a “buy” rating and set a $40.00 price target (up from $36.00) on shares of Damora Therapeutics, Inc. Common Stock in a research report on Tuesday, February 17th. UBS Group initiated coverage on Damora Therapeutics, Inc. Common Stock in a research note on Tuesday, February 17th. They issued a “buy” rating and a $45.00 price objective on the stock. Finally, Royal Bank Of Canada assumed coverage on Damora Therapeutics, Inc. Common Stock in a research note on Friday, April 24th. They issued an “outperform” rating and a $40.00 target price for the company. Two investment analysts have rated the stock with a Strong Buy rating, five have given a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Damora Therapeutics, Inc. Common Stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $42.00.

Check Out Our Latest Stock Report on DMRA

Damora Therapeutics, Inc. Common Stock Stock Performance

The company has a market capitalization of $1.29 billion, a price-to-earnings ratio of -3.77 and a beta of 1.46. The company has a 50-day moving average price of $24.95 and a 200-day moving average price of $25.30.

Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA – Get Free Report) last issued its quarterly earnings data on Wednesday, May 13th. The company reported ($0.62) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.23). As a group, sell-side analysts anticipate that Damora Therapeutics, Inc. Common Stock will post -2.1 earnings per share for the current fiscal year.

Institutional Trading of Damora Therapeutics, Inc. Common Stock

Several institutional investors have recently modified their holdings of DMRA. Two Sigma Investments LP bought a new position in Damora Therapeutics, Inc. Common Stock during the 3rd quarter worth $76,000. Virtu Financial LLC acquired a new position in shares of Damora Therapeutics, Inc. Common Stock in the third quarter worth approximately $49,000. Connective Capital Management LLC acquired a new position in shares of Damora Therapeutics, Inc. Common Stock in the 3rd quarter worth approximately $100,000. Sigma Planning Corp bought a new stake in Damora Therapeutics, Inc. Common Stock during the fourth quarter valued at $334,000. Finally, Geode Capital Management LLC acquired a new stake in Damora Therapeutics, Inc. Common Stock during the 4th quarter worth about $266,000. Institutional investors own 14.20% of the company’s stock.

About Damora Therapeutics, Inc. Common Stock

(Get Free Report)

Galecto Inc is a clinical‐stage biotechnology company developing small‐molecule therapies that target key pathways involved in fibrotic and malignant diseases. The company’s research focuses on inhibiting galectin‐3, an extracellular carbohydrate‐binding protein implicated in inflammation, fibrosis and tumor progression, as well as lysyl oxidase‐like 2 (LOXL2), an enzyme that crosslinks collagen and elastin in fibrotic tissue.

Its lead programs include GB0139, an inhaled galectin‐3 inhibitor in Phase II trials for idiopathic pulmonary fibrosis and other fibrosing lung diseases, and GB1211, an oral galectin‐3 inhibitor being evaluated for systemic fibrotic disorders.

Featured Articles